Sterling ADC expansion

CDMO Sterling Pharma Solutions has announced a $3 million investment in antibody-drug conjugate (ADC) development and manufacturing at its facility at Germantown, Wisconsin. It has commissioned a dedicated GMP suite, which will incorporate a modular isolator with containment capabilities down to less than 1 ng/m3.

The isolator can manufacture toxin linkers at up to kilogram scale, which can then be transferred to Deeside, UK, for the development and final-phase GMP conjugations of ADC drugs. This will also facilitate weighing, dispensing and dissolving of reagents within a fully contained environment.

Additional modules for automated flash, and high-pressure chromatography under a range of normal and reverse-phase conditions, as well as in-process analysis of products have also been installed. A further module, which will allow lyophilisation of up to 30-litre batches at -85°C, is currently being commissioned.